Emetine and the alternative splicing of Bcl-X: where to next?

Jacqueline C Shultz; Charles E Chalfant

doi:10.1016/j.chembiol.2007.12.002

Emetine and the alternative splicing of Bcl-X: where to next?

Chem Biol. 2007 Dec;14(12):1313-4. doi: 10.1016/j.chembiol.2007.12.002.

Authors

Jacqueline C Shultz¹, Charles E Chalfant

Affiliation

¹ Department of Biochemistry, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0614, USA.

PMID: 18096499
DOI: 10.1016/j.chembiol.2007.12.002

Abstract

Interference with the alternative splicing of apoptotic factors offers an innovative and specific mechanism to target malignant cells. In this issue of Chemistry & Biology, Zhou et al. report on the regulation of the alternative splicing of Bcl-x pre-mRNA in response to emetine, a potent protein synthesis inhibitor, as well as define a major player in the signaling mechanism.

Publication types

Comment

MeSH terms

Alternative Splicing / drug effects*
Apoptosis / drug effects
Cell Line, Tumor
Emetine / pharmacology*
Enzyme Inhibitors / pharmacology
Gene Expression Regulation, Neoplastic / drug effects
Humans
Models, Biological
Neoplasms / genetics
Neoplasms / metabolism
Neoplasms / pathology
Protein Phosphatase 1 / antagonists & inhibitors
Protein Phosphatase 1 / metabolism
Signal Transduction / drug effects
bcl-X Protein / genetics*

Substances

Enzyme Inhibitors
bcl-X Protein
Protein Phosphatase 1
Emetine